Select publications

Atkins MB et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004;22(5):909-18. Abstract

Azad N et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. Presentation. ASCO 2006;Abstract 3004.

Brugarolas J. Renal-cell carcinoma — Molecular pathways and therapies. N Engl J Med
2007;356(2):185-7. No abstract available

Bukowski RM et al. Bevacizumab with or without erlotinib in metastatic renal cell carci­noma (RCC). Proc ASCO 2006;Abstract 4523.

Escudier B et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-34. Abstract

Genentech BioOncology. Interim analysis of phase III trial shows Avastin plus interferon therapy improved progression-free survival in patients with previously untreated advanced renal cell carcinoma. Available at http://www.gene.com/gene/news/press-releases/index.jsp

Hudes G et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). Proc ASCO 2006;Abstract LBA4.

Motzer RJ et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med 2007;356(2):115-24. Abstract

Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: Role of the HIF system. Nat Med 2003;9(6):677–84. Abstract

Rini BI et al. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 2004;10(8):2584-6. Abstract

Ryan CW et al. Sorafenib plus interferon-alpha2b as first-line therapy for advanced renal cell carcinoma: SWOG 0412. Proc ASCO 2006;Abstract 4525.

Yang JC et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427-34. Abstract

Home

Interviews
Brian I Rini , MD
- Select publications

Robert A Figlin, MD
- Select publications

MIchael B Atkins , MD
- Select publications

CME Information

Faculty Disclosures

Editor's Office